Pablo Mojica-Manosa, MD
Surgical Oncology · Hato Rey, PRNPI 1679632756
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,358 of the $6,983 with a category attached, or 62.4%. 39 manufacturers reported payments, led by Merck at 42.3% of the total. 2025 is the largest year on record at $2,475, 3.4 times the $732 reported in 2019.
Across 205 payments — averaging $34.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- Johnson & Johnson$767
- AbbVie$329
- AstraZeneca$242
- Eli Lilly Export S.A. Puerto Rico Branch$168
- Amgen$166
- plus $2K from 33 others
What the payments were for
- Consulting fees$1,50021%
- Speaking & faculty fees$1,12516%
- Food & beverage$4,35862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 17 | $2,957 |
| Johnson & Johnson | 37 | $767 |
| AbbVie | 15 | $329 |
| AstraZeneca(2 entities) | 11 | $242 |
| Eli Lilly Export S.A. Puerto Rico Branch | 8 | $168 |
| Amgen | 9 | $166 |
| E.r. Squibb & Sons, L.L.C. | 8 | $160 |
| Puma Biotechnology, Inc. | 8 | $152 |
| Johnson And Johnson International | 2 | $138 |
| Ipsen Biopharmaceuticals, Inc | 6 | $138 |
| Incyte Corporation | 6 | $137 |
| Eisai Inc. | 7 | $127 |
| Regeneron Healthcare Solutions, Inc. | 5 | $116 |
| Bristol Myers Squibb | 4 | $114 |
| Genentech USA, Inc. | 5 | $103 |
| Sobi, Inc | 5 | $103 |
| Sanofi | 5 | $90 |
| PBG Puerto Rico LLC | 5 | $89 |
| Bayer Puerto Rico Inc. | 4 | $89 |
| Seagen Inc. | 4 | $85 |
| Taiho Oncology, Inc. | 4 | $81 |
| Morphosys, US Inc. | 3 | $66 |
| Springworks Therapeutics, Inc. | 3 | $63 |
| Novartis | 3 | $56 |
| Exelixis Inc. | 2 | $52 |
| Stryker | 1 | $48 |
| Beigene USA, Inc. | 3 | $43 |
| Verity Pharmaceuticals Inc. | 2 | $42 |
| Caris MPI, Inc. | 2 | $37 |
| Sun Pharmaceutical Industries Inc. | 2 | $36 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Tolmar, Inc. | 1 | $24 |
| Pharmaand GmbH | 1 | $24 |
| Medtronic | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Partner Therapeutics, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
| EMD Serono, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few surgical oncology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynthroidLevothyroxine Sodium | 27 | $1,744 |
| Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen | 69 | $482 |
| Ciprofloxacin Hcl | 23 | $176 |
| Pantoprazole Sodium | 14 | $127 |
| Metoclopramide Hcl | 13 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $329 | $1,74427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few surgical oncology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.
Other surgical oncology in Hato Rey
- Jorge Toro-BurguetePonce$3K
- Edna Mora PineroSan Juan$2K
- Kathia Alejandro-SerranoManati$2K
- Reynold LopezSan Juan$1K
- Carlos Santiago SanchezToa Baja$288
- Angel Rodriguez RiveraSan Juan$222
- Jose Cebollero MarcucciGuayama$158
- Jorge JustinianoSan German$65
- Sonia Ortiz PaganCayey$54
- Francisco Amador RamirezSan Juan$44
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.